- « Previous
- Clinical Pharmacology
- Next »
Primaxin IM
Clinical Pharmacology
Primaxin IM
Standardized susceptibility test procedures require the use of laboratory control organisms. Standard imipenem powder should provide the following MIC values:
| Organism | MIC (μ g/mL) |
| E. coliATCC 25922 | 0.06-0.25 |
| S. aureus ATCC 29213 | 0.015-0.06 |
| E. faecalis ATCC 29212 | 0.5-2.0 |
| P. aeruginosa ATCC 27853 | 1.0-4.0 |
Diffusion techniques
Quantitative methods that require measurement of zone diameters give the most precise estimate of antibiotic susceptibility. One such standard procedure2, which has been recommended for use with disks to test susceptibility of organisms to imipenem, uses the 10-μg imipenem disk. Interpretation involves the correlation of the diameters obtained in the disk test with the minimum inhibitory concentration (MIC) for imipenem.
Reports from the laboratory giving results of the standard single-disk susceptibility test with a 10-μg imipenem disk should be interpreted according to the following criteria:
| Zone Diameter (mm) | Interpretation |
| ≥ 16 | Susceptible |
| 14-15 | Moderately Susceptible |
| ≤ 13 | Resistant |
Standardized procedures require the use of laboratory control organisms. The 10-μg imipenem disk should give the following zone diameters:
| Organism | Zone Diameter (mm) |
| E. coli ATCC 25922 | 26-32 |
| P. aeruginosa ATCC 27853 | 20-28 |
For anaerobic bacteria, the MIC of imipenem can be determined by agar or broth dilution (including microdilution) techniques3.
The MIC values obtained should be interpreted according to the following criteria:
| MIC (μ g/mL) | Interpretation |
| ≤ 4 | Susceptible |
| 8 | Moderately Susceptible |
| ≥ 16 | Resistant |
REFERENCES
1. National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically — Fourth Edition. Approved Standard NCCLS Document M7-A4, Vol. 17, No. 2 NCCLS, Villanova, PA, 1997.
2. National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disk Susceptibility Tests — Sixth Edition. Approved Standard NCCLS Document M2-A6, Vol. 17, No. 1 NCCLS, Villanova, PA, 1997.
3. National Committee for Clinical Laboratory Standards, Method for Antimicrobial Susceptibility Testing of Anaerobic Bacteria — Third Edition. Approved Standard NCCLS Document M11-A3, Vol. 13, No. 26 NCCLS, Villanova, PA, 1993.
Generic Name: Imipenem and Cilastatin
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
3D Mammogram
Learn how new technology may change the way breast cancer is diagnosed and in turn, save more lives. See more WebMD Videos »
ENABLEX is a prescription medicine used in adults to treat the following symptoms due to a condition called overactive bladder:
- · having a strong need to go to the bathroom right away (also called "urgency")
- · leaks or wetting accidents (also called "urinary incontinence")
- · having to go to the bathroom too often (also called "urinary frequency")
IMPORTANT SAFETY INFORMATION
You should not take once-daily ENABLEX if you have certain types of stomach problems, glaucoma, or have trouble emptying your bladder. Side effects of ENBLEX include blurred vision, and more commonly dry mouth, constipation, indigestion, and abdominal pain. Use caution when doing certain activities until you know how ENBALEX affects you.

